Poly[[μ-(1-ammonio­ethane-1,1-di­yl)bis­(hydrogenphospho­nato)]diaquachloridodisodium]: a powder X-ray diffraction study

The title compound, [Na2(C2H8NO6P2)Cl(H2O)2]n, has a polymeric two-dimensional structure extending parallel to (001). The asymmetric unit contains two Na+ cations located on a centre of symmetry and on a mirror plane, respectively, one half of a bis-phospho­nate anion (the entire anion is completed by mirror symmetry), one chloride anion on a mirror plane and one water mol­ecule in general positions. The two Na+ cations exhibit distorted octa­hedral NaCl2O4 coordination polyhedra, each consisting of two deprotonated O atoms of the bis-phospho­nate anion, of two water mol­ecules and of two chloride anions. Strong O—H⋯O hydrogen bonds between the –OH group and one of the free O atoms of the bis-phospho­nate anion connect adjacent layers along [100], supported by N—H⋯Cl inter­actions. Intra­layer O—H⋯O and N—H⋯O hydrogen bonds are also observed

Iaea contribution to the development of ⁶⁴cu radiopharmaceuticals for theranostic applications

Copper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes. Cu-64 is a radionuclide that reflects the natural biochemical pathways of Cu-64 ions, therefore, can be exploited for the detection and therapy of certain malignancies and metabolic diseases. Beside these applications of Cu-64 ions, this radionuclide can be also used for radiolabelling bifunctional chelators carrying a variety of pharmacophores for targeting different biological substrates. These include peptide-based substrates and immunoconjugates as well as small-molecule bioactive moieties. Fueled by the growing interest of Member States (MS) belonging to the International Atomic Energy Agency (IAEA) community, a dedicated Coordinated Research Project (CRP) was initiated in 2016, which recruited thirteen participating MS from four continents. Research activities and collaborations between the participating countries allowed for collection of an impressive series of results, particularly on the production, preclinical evaluation and, in a few cases, clinical evaluation of various 64Cu-radiopharmaceuticals that may have potential impact on future development of the field. Since this CRP was finalized at the beginning of 2020, this short review summarizes outcomes, outputs and results of this project with the purpose to propagate to other MS and to the whole scientific community, some of the most recent achievements on this novel class of theranostic 64Cu-radiopharmaceticals